Primary pancreatic signet ring cell carcinoma: molecular mechanisms and advances in clinical diagnosis and treatment

原发性胰腺印戒细胞癌:分子机制及临床诊断和治疗进展

阅读:1

Abstract

PURPOSE: To comprehensively integrate current evidence on the molecular mechanisms, diagnostic approaches, and treatment options for primary pancreatic signet ring cell carcinoma (PPSRCC), guiding clinical decision-making and improving prognosis. METHODS: In addition to the narrative synthesis, we performed a targeted extraction and comparative synthesis of published patient-level cases, case series, and registry studies to generate pooled clinicopathologic summaries, propose an operational diagnostic workflow (imaging-EUS-FNA-IHC-molecular testing), and formulate PPSRCC-specific management recommendations. RESULTS: Primary pancreatic signet ring cell carcinoma (PPSRCC) is a rare pancreatic cancer subtype with extremely high malignancy and very poor prognosis. Current research on this disease is limited with weak evidence, leading to insufficient clinical awareness. PPSRCC exhibits unique epidemiological characteristics, molecular mechanisms, and clinical diagnostic and therapeutic features. Molecular studies suggest that its carcinogenic pathways involve abnormal activation of the ErbB2/ErbB3-MUC4 axis, activation of the PI3K and MAPK pathways, and frequent mutations in classical pancreatic cancer driver genes such as KRAS; however, the lack of specific molecular biomarkers and typical imaging findings makes clinical diagnosis challenging. In terms of treatment, clinical practice mostly refers to the therapeutic strategies for pancreatic ductal adenocarcinoma (PDAC), primarily surgery combined with radiochemotherapy. Targeted therapies against KRAS mutations and immunotherapy targeting PD-L1 may provide new directions for future management. In-depth elucidation of the molecular features of PPSRCC, clarification of diagnostic and therapeutic strategies, and development of novel targeted agents are key to improving clinical outcomes. CONCLUSIONS: Deeper mechanistic interrogation and standardized diagnostic workflows are needed to enable earlier detection and tailored therapy in PPSRCC. Multidisciplinary care and emerging precision strategies may improve outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。